Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises EQT in connection with sale of Swedegas
Mandate

Vinge advises EQT in connection with sale of Swedegas

March 23, 2015

Vinge advises EQT Infrastructure in connection with the sale of Swedegas to a consortium of Enagás Internacional S.L.U., part of Spain’s leading natural gas transmission company Enagás S.A., and Fluxys Europe B.V., part of the Belgium-based natural gas infrastructure group Fluxys SA. Swedegas owns and operates Sweden’s entire gas transmission network, extending from Dragör in Denmark to Stenungsund in Sweden. The transaction is expected to close in mid-April.

Vinge’s team consists of responsible partner Daniel Rosvall together with Matthias Pannier and Oscar Rydén (corporate), Carl Johan af Petersens, Johan Cederblad and Helena Wanhainen (regulatory).

Related

Vinge advises Trianon in connection with directed share issue and tender offer for subordinated sustainable capital securities

 Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with a directed share issue of SEK 184 million and a tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
April 19, 2024

Vinge advises Blackstone in connection with its investment in Winthrop Technologies

 Vinge, as local Swedish counsel, advised Blackstone Tactical Opportunities and affiliated funds (“Blackstone”) in connection with a strategic partnership with Winthrop Technologies Limited (“Winthrop Technologies”).
April 17, 2024

Vinge has advised Hansa Biopharma in connection with a directed share issue of SEK 372 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of SEK 372 million before transaction costs. Hansa Biopharma is a commercial-stage biopharmaceutical company pioneering the development and commercialization of innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa Biopharma’s ordinary share is listed on Nasdaq Stockholm.
April 16, 2024